Garcinol

Garcinol: A Comprehensive Encyclopedic Reference

1. Identity: Chemical and Botanical Profile

1.1 Chemical Identity

Garcinol — systematic IUPAC name (1S,3E,5R,7R)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)-1-[(2S)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]bicyclo[3.3.1]nonane-2,4,9-trione — is a polyphenol of the polyisoprenylated benzophenone class extracted from the rind of the Garcinia indica fruit, found extensively in tropical regions. The principal antioxidant substance of Garcinia indica and other species, it is also called camboginol, and is structurally classified as a tri-isoprenylated chalcone derivative.

Chemically, garcinol is a polyisoprenylated benzophenone with a molecular weight of 602.812 g/mol, possessing strong anti-inflammatory and antioxidant properties. The chemical structure of garcinol contains a β-diketone moiety and phenolic hydroxyl groups, making it structurally similar to the antioxidant curcumin. Garcinol is a yellow fat-soluble pigment, while its structural isomer isogarcinol is colourless. Studies of garcinol's chemical structure reveal that the C-3 ketonic group and phenolic ring with hydroxyl attachments are the oxidation sites; 1,2-carbon double bond α,β-unsaturated ketones have been found to be crucial for apoptosis induction; and double bonds in the isoprenyl ring are responsible for antioxidative properties, while 13,14-dihydroxy groups and C8 side chains are key functional groups for anti-cancer effects as shown in in vitro experiments.

1.2 Botanical Source

Garcinol and its structural isomer isogarcinol are secondary plant metabolites isolated from various Garcinia species, most prominently Garcinia indica. Garcinia indica belongs to the botanical family Clusiaceae (formerly Guttiferae). Garcinia indica is a slow-growing tree with horizontal, drooping branches that can grow up to 15 metres in height; it is a native plant of India and belongs to the Guttiferae family, and is also commonly known as Indian mangosteen or kokum.

Garcinol is primarily present in the family Clusiaceae and genus Garcinia, and although Garcinia indica is the most commonly referenced species in the scientific literature, it is found in other plant species as well; the genus Garcinia includes approximately 200 species located throughout Asia and Africa.

Dried fruit of G. indica contains around 2.5% garcinol when measured with High-Performance Thin Layer Chromatography (HPTLC). High yields of garcinol can be obtained from dried kokum (Garcinia indica) plums; up to 5 g from 500 g dried kokum plums can be achieved by extraction with methanol, followed by column chromatography, with crystallization from hexane yielding yellow needles.

1.3 Co-occurring Phytochemicals

Chemical studies have shown that the rind of Garcinia indica contains protein, tannin, pectin, sugars, fat, organic acids including (−)-hydroxycitric acid, hydroxycitric acid lactone and citric acid; the anthocyanins cyanidin-3-glucoside and cyanidin-3-sambubioside; and the polyisoprenylated phenolics garcinol and isogarcinol. The fruit composition of Garcinia indica also contains garcinol, xanthochymol, isoxanthochymol, and hydroxycitric acid as major active chemicals.

1.4 Common Forms and Preparations

Garcinol is used as an active ingredient in various topical products for its antioxidant activity. It is also used as an additive ingredient in hydroxycitric acid formulations, purported by some commercial manufacturers to improve lean body mass.

Garcinol's extreme insolubility in water remains the main obstacle for its clinical application; to address this, researchers have reported the formulation of garcinol entrapped in PLGA nanoparticles by nanoprecipitation using vitamin E TPGS as an emulsifier. Garcinol is also formulated wrapped in nanoparticles, which enhance its solubility and target tumour locations. Controlled release of garcinol specifically in the colon is made possible by using pH-responsive nanoparticles. In conventional supplement commerce, garcinol-standardised extracts (such as 40% garcinol preparations) derived from dried fruit rind are also available in encapsulated form.

2. Traditional and Historical Use

Garcinol is isolated from fruit rinds of Garcinia indica, which has been used as an ornament, food ingredient, and traditional medicine for centuries. Commonly known as kokum and belonging to the Guttiferae family, it is a plant native to certain regions of India; the trees yield fruits annually in the summer season during the months of March to May. The fruits are green when raw and red to dark purple when fully ripe, and are used to prepare juice, pickles, and as an acidulant in curries.

In the traditional Indian system of medicine, Ayurveda, and in various folk systems of medicine, the fruit rinds and leaves are used to treat various inflammatory ailments, rheumatic pain, and bowel complaints. Kokum butter prepared from the seed is of both commercial and medicinal use.

Garcinol, found primarily in the rind of the Garcinia indica fruit (commonly known as kokum), has a long-standing history of medicinal use especially in traditional Indian and Southeast Asian practices. Historically, kokum fruit and its extracts were utilised for their digestive, anti-inflammatory, and antioxidant properties. Herbal preparations made from kokum rinds are used in the treatment of inflammatory ailments, rheumatic pains, and bowel complaints; the fruit is also considered to be anthelmintic and cardiotonic.

Parts or extracts of Garcinia cambogia (Malabar tamarind) and Garcinia indica (kokum), grown in Africa, Asia, and the Western Ghats of India, have been used in the traditional Ayurvedic medical system to treat various gastric ailments and skin-related problems because of their therapeutic efficiency.

3. Key Constituents and Active Compounds

3.1 Garcinol as Principal Bioactive

Garcinol, anthocyanins, and hydroxycitric acid are the important chemical constituents of Garcinia indica and are identified as responsible for most of its medicinal properties. Among these, garcinol is of greatest research interest due to its distinctive polyisoprenylated benzophenone scaffold and pleiotropic biological activities.

3.2 Structural Basis of Activity

Garcinol's action in biological systems is based on its antioxidant and anti-inflammatory properties, but also on its potency to inhibit histone acetyltransferases (HATs). Recent studies indicate that garcinol may also deregulate the expression of miRNAs involved in tumour development and progression.

Garcinol is an inhibitor of the histone acetyltransferases (HAT) p300 and PCAF, with roles in neurocytes, immunocytes, and cancer cells. Garcinol has been reported to have many beneficial biological activities including anticancer, antioxidant, and anti-inflammatory activities. Even though its biological effects are likely complex and may operate through multiple targets, evidence suggests that some of its effects are mediated through HDAC11 inhibition; notably, several in vivo effects of garcinol showed similarity with HDAC11 knockout phenotypes.

4. Mechanisms of Action

4.1 Antioxidant Mechanisms

There is ample data to suggest potent antioxidant properties of garcinol, which have been used to explain most of its observed biological activities. However, emerging evidence suggests that garcinol could be useful as an anti-cancer agent, and it is increasingly recognised that garcinol is a pleiotropic agent capable of modulating key regulatory cell signalling pathways. Several studies have demonstrated its capacity to scavenge free radicals and to stop the inflammatory cascade.

4.2 Anti-inflammatory Mechanisms

Co-incubation of garcinol with LPS inhibited the production of pro-inflammatory cytokines including TNF-α, IL-8, IL-6, IL-1β, and pro-inflammatory mediators including iNOS and COX-2 at the mRNA and protein expression levels. Garcinol also decreased the secretion of TNF-α, IL-6, IL-1β, PGE2, and NO in macrophage cell models.

Previous studies suggest that garcinol isolated from Garcinia cambogia inhibited the activation of NF-κB and JAK/STAT-1 signalling pathways in LPS-activated macrophages.

4.3 Epigenetic Mechanisms: HAT and HDAC Inhibition

Garcinol's action in cancer cells is based on its antioxidant and anti-inflammatory properties, but also on its potency to inhibit histone acetyltransferases (HATs). The HAT targets primarily include p300 and PCAF — coactivator proteins that regulate transcription of genes involved in proliferation, differentiation, and apoptosis. Garcinol may be considered as a candidate for next-generation epigenetic drugs, but further studies are needed to establish precise toxicity, dosages, routes of administration, and safety for patients.

Garcinol can rescue brain precursor cells, encourage their fast development, and successfully restore the equilibrium among the neurotransmitters glutamate and GABA. It suppresses HAT effectively. Both histone acetylase and deacetylase inhibitors have been used to target accelerated neurodegeneration in Alzheimer's disease brain caused by the disruption in histone dysregulation status.

4.4 Anti-cancer Signalling Pathways

Garcinol exerts its anticancer effects by affecting multiple intracellular pathways. Previous studies have suggested that garcinol could inhibit cancer cell proliferation through inhibition of STAT-3, NF-κB, and PI3K/AKT signalling pathways. Substantial molecular exploration of garcinol-mediated effects has also indicated that it mediates the inhibition of key cellular pathways associated with cancers, including ERK1/2, PI3K/AKT, STAT3, Wnt/β-catenin, and the NF-κB pathway.

Garcinol triggers apoptosis by the inhibition of STAT3 and NF-κB pathways (anti-apoptotic pathways), and downregulates anti-apoptotic protein Bcl-2 while upregulating Bax, which undergoes a conformational change and translocates to the mitochondria, oligomerizing to form pores in the mitochondrial outer membrane.

Garcinol mediates the inhibition of NF-κB and decreases the expression of genes associated with cell survival (Bcl-XL, Bcl-2, and survivin) and proliferation (cyclin D1).

5. Scientific Evidence by Area of Use

5.1 Anticancer Activity

Garcinol, a polyisoprenylated benzophenone extracted from the rind of the fruit of Garcinia indica, has been consumed traditionally for centuries, but its biological activities — specifically its anticancer potential — are the result of recent scientific investigations. The anticarcinogenic properties appear to be moderated via its antioxidative, anti-inflammatory, antiangiogenic, and proapoptotic activities.

Breast Cancer (in vitro): Studies found that garcinol exhibits dose-dependent cancer cell-specific growth inhibition in both MCF-7 and MDA-MB-231 cell lines, with a concomitant induction of apoptosis, and has no effect on non-tumorigenic MCF-10A cells. These results indicated induction of caspase-mediated apoptosis in highly metastatic MDA-MB-231 cells, with down-regulation of NF-κB signalling as the mechanism. Garcinol inhibited constitutive NF-κB activity, consistent with down-regulation of NF-κB-regulated genes.

Pancreatic Cancer (in vitro): Two human pancreatic cancer cell lines, BxPC-3 and Panc-1, with wild and mutant K-ras respectively, were treated with garcinol at 0–40 µM. Garcinol significantly inhibited cell growth by induction of apoptosis in a dose- and time-dependent manner, and flow cytometric analysis revealed G0-G1 phase cell cycle arrest in both cell lines. The molecular mechanisms investigated targeted signalling moieties involved in apoptosis (X-IAP, cIAP, caspase-3, 9, and PARP cleavage), transcription factor NF-κB, and molecules associated with neovascularization and metastasis (MMP-9, VEGF, IL-8, and PGE2).

Endometrial Cancer (in vitro): In endometrial cancer cell lines (ISH and HEC-1B), garcinol treatment upregulated the expression of tumour suppressor proteins p53 and p21, and downregulated their target proteins CDK4, cyclin D1, and cyclin B1. Garcinol arrested the cell cycle at different points in the two cell lines, suggesting some other, as yet unidentified, pathways may also be involved.

Colon Cancer (in vitro): Garcinol showed potent inhibitory growth activity against HT-29 and HCT-116 colon cancer cells.

Leukemia (in vitro): Garcinol exhibited greater induction of apoptosis than curcumin in human leukemia HL-60 cells.

Gastrointestinal Cancers (preclinical review, 2024): Garcinol exhibits anticancer effects in esophageal, gastric, colorectal, pancreatic, and liver cancers by inhibiting metastasis, inducing apoptosis, and targeting key molecular pathways in cancer progression. Nanotechnology is explored as a means to enhance garcinol delivery and efficacy. Safety assessments suggest a promising toxicity profile.

Multiple cancer types: The anticancer function of garcinol has been reported in several types of cancer cells, such as colon, prostate, liver, lung, breast, esophageal, pancreatic, and oral cancer cells.

Evidence characterisation: Several studies have shown anti-cancer properties of garcinol in cancer cell lines and experimental animal models. As of current reporting, no completed human clinical trials on garcinol as an anticancer agent have been published. The available evidence is entirely preclinical (in vitro and in vivo animal studies). Future research is needed on optimising delivery, exploring synergistic combinations, and conducting clinical trials to validate efficacy and safety for clinical applications.

5.2 Anti-inflammatory Activity

One key study investigated the anti-inflammatory effect of garcinol isolated from Garcinia dulcis fruit in LPS-activated THP-1 and Raw 264.7 macrophages. The results demonstrated that low concentrations of garcinol did not alter cell viability. Co-incubation of garcinol with LPS inhibited the production of pro-inflammatory cytokines including TNF-α, IL-8, IL-6, IL-1β, and pro-inflammatory mediators iNOS and COX-2 at mRNA and protein expression levels. Additionally, an in vitro study of IL-1β-activated chondrocytes suggested a protective effect of garcinol by inhibiting the secretion of pro-inflammatory molecules including TNF-α, IL-6, iNOS, and COX-2 expression.

These studies demonstrate that inhibition of inflammatory pathways via multiple but related targets may play a pivotal role in garcinol's response as an anti-inflammatory and anticarcinogenic agent. Evidence is presently limited to in vitro and animal studies; no human clinical trials examining garcinol specifically as an anti-inflammatory agent have been identified in the literature.

5.3 Antioxidant Activity

With its unusual chemical structure, garcinol has generated considerable research interest because of its remedial qualities against many human diseases and ailments, mostly attributed to its potent antioxidant capabilities. There is ample data to suggest potent antioxidant properties of this compound, which have been used to explain most of its observed biological activities. The evidence base for antioxidant activity rests on in vitro free-radical scavenging assays and some in vivo animal models. Human clinical antioxidant data are absent.

5.4 Neuroprotection and Neurodegenerative Disease

Garcinol exhibits profound antioxidant and anti-inflammatory properties, contributing to its promising neuroprotective action. Recent reports disseminate the capacity of garcinol to influence neuronal growth and survival, altering the neurochemical status in the brain and regulating memory and cognition. The concomitant neuro-rescue property of garcinol may render it an effective therapeutic in Alzheimer's disease (AD). Emerging data relating histone acetylation abnormalities to the course of neurodegenerative disorders provides a basis to explore garcinol as an anti-AD therapeutic.

Garcinol provided a neuroprotective effect by decreasing nitric oxide production and the expression of lipopolysaccharide-induced inflammatory mediators, iNOS and COX-2, in rat cortical astrocyte cultures.

Garcinol effectively blocked MPP+-mediated ROS formation by activating the DJ-1/SIRT1 and PGC-1α-mediated antioxidant pathway; further findings indicated that activated SIRT1 can also regulate p-AMPK-mediated autophagy to protect neurons from damage, suggesting that garcinol sub-sequentially regulates intracellular autophagy.

Since the antioxidant and anti-inflammatory effects of garcinol are well documented, a possible neuroprotective role can be expected and elaborated. The regulation of memory and cognition has been achieved through the use of garcinol, which influences neuronal growth and survival.

Evidence characterisation: All current neuroprotection data are from cell-culture models, rodent studies, and in silico/computational analyses. Clinical studies are necessary to confirm these effects and understand the underlying molecular mechanisms comprehensively.

5.5 Gastrointestinal Health and Anti-ulcer Activity

The mechanism of action for garcinol's gastric mucosal protection may be associated with the interaction of garcinol with reactive oxygen species on the surface of gastric mucosa. In vitro, the bactericidal activities of clarithromycin and garcinol exerted time- and concentration-dependent effects on Helicobacter pylori. In the same study, garcinol exhibited greater bactericidal activity on H. pylori when compared with resveratrol.

Garcinol (a polyisoprenylated benzophenone analog with a molecular formula C₃₈H₅₀O₆) was found to be the most potent among three bioactive molecules of G. morella (garcinol, hydroxycitric acid, and hydroxycitric acid lactone) that could prevent intestinal barrier disruption. Investigators assessed its efficacy in preventing intestinal inflammation and NAFLD progression in a high-fat diet-induced NAFLD mouse model, also elucidating the impact on gut microbiome modulation and intestinal barrier function.

Evidence characterisation: Evidence for anti-ulcer and gastrointestinal benefits is based on in vitro studies and animal models. No human clinical trial data specific to garcinol for gastrointestinal conditions are available in the identified literature.

5.6 Bone Health (Osteoclast Activity)

In vitro, garcinol showed strong inhibitory activity on osteoclast formation and bone resorption, results that were supported by protection against osteolytic bone loss in a mouse model. The mechanism involved inhibition of several signalling pathways that promote expression of osteoclastic-related genes. Clinical trial data supporting use are limited.

5.7 Metabolic Health (Antidiabetic, Antiobesity)

Reviews of the literature report appetite suppressant effects and activity in models of diabetes and cardiovascular disease. Recent works have documented potential applications of garcinol including antimicrobial, antioxidant, anticancer, anti-inflammatory, hepatoprotective, antiobesity, and neuroprotective activities. These findings are based primarily on animal models and in vitro studies; robust human clinical evidence for metabolic endpoints specific to garcinol is absent.

5.8 Overall Evidence Characterisation

Numerous in vitro and scientific animal studies on garcinol document anti-inflammatory, antioxidant, anticancer, and antibacterial activity. Clinical data are lacking. This is the defining limitation of the garcinol evidence base as of the current literature: a rich and promising body of cell-based and animal research has not yet been validated in human trials.

6. Body Systems and Health Areas

Chemical constituents extracted from different parts of Garcinia indica possess anticancer, antiulcer, antioxidative, antiglycation, antitumour activity, among others. Based on the available research, garcinol is associated with the following body systems and health areas:

• Oncology: Garcinol could be useful as an anti-cancer agent, and is increasingly being recognised as a pleiotropic agent capable of modulating key regulatory cell signalling pathways.
• Immune and inflammatory system: Inhibition of NF-κB, COX-2, iNOS, and pro-inflammatory cytokines (in vitro and animal data).
• Nervous system: Garcinol shows promise in neuroprotection, mitigating oxidative stress and neuroinflammation, which are pivotal in the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's.
• Gastrointestinal system: Anti-ulcer activity, intestinal barrier protection, and activity against H. pylori (preclinical).
• Skeletal system: Anti-osteoclastic activity in vitro and animal models.
• Epigenetic regulation: HAT (p300/PCAF) inhibition and potential HDAC11 inhibition, with relevance to cancer and neurodegeneration.
• Cardiovascular and metabolic: Preliminary evidence in animal and in vitro models for anti-obesity, antidiabetic, and cardioprotective effects.

7. Dosage Forms and Reported Dosages

No standardised human clinical dosage has been established for isolated garcinol, as controlled clinical trials are absent. The following are dosages as reported in the cited scientific literature:

• In vitro cancer studies: For pancreatic cancer cell lines, garcinol was tested at concentrations of 0–40 µM.
• In vitro inflammatory studies: Garcinol at concentrations of 10, 20, and 30 µM was tested in NF-κB signalling pathway studies in LPS-treated THP-1 and RAW 264.7 cells.
• Rodent safety/efficacy studies: In acute safety studies in Wistar rats, 40% garcinol did not show any adverse effect at a high single dose of 2000 mg/kg. There were no treatment-related changes at the highest dose of 100 mg/kg/day in 28-day repeated dose oral toxicity, 90-day repeated dose oral toxicity, and reproductive/developmental toxicity studies.
• Standardised extract efficacy studies: Sami Labs Limited standardised 40% garcinol preparation for efficacy studies at doses not exceeding 10 mg/kg with significant outcomes.
• Dietary administration: No toxic effects of garcinol have been reported even when given orally at up to 0.05% in diet in animal studies.
• Garcinia extracts (upper limit in toxicological modelling): Toxicological studies suggest an upper limit of 2,800 mg/day of Garcinia extracts or hydroxycitric acid, based on the "no observed adverse effect level."

8. Safety Considerations and Drug Interactions

8.1 Preclinical Safety Profile

In acute safety studies in Wistar rats, 40% garcinol did not show any adverse effect at a high single dose of 2000 mg/kg and can be classified as GHS category 5/unclassified according to the Globally Harmonized Classification System. There were no treatment-related changes at the highest dose of 100 mg/kg/day in 28-day repeated dose oral toxicity, 90-day repeated dose oral toxicity, and reproductive/developmental toxicity studies. It can thus be concluded that 40% garcinol has a low toxicity profile in rodents under the experimental conditions applied.

Most reports suggest dietary administration of garcinol in animal studies exhibits low toxicity, with animal studies finding no histological or pathological changes in liver, kidney, lung, heart, or esophageal organ systems.

The acute and sub-chronic toxicity of 40% standardised garcinol was evaluated in rodents with OECD criteria in mind. The toxicity of garcinol to rodents was found to be minimal; on clinical symptoms, behaviour, development, reproduction, or histology, no negative consequences were observed.

8.2 Reproductive and Developmental Considerations

Toxicity towards spermatogenesis and testicular atrophy in rats from administered G. cambogia extract has been reported. Information regarding safety and efficacy in pregnancy and lactation is lacking.

8.3 Cytochrome P450 Interactions (Herb–Drug Interactions)

In rat liver microsome studies, garcinol showed strong inhibition of CYP1A2 (IC₅₀ 7.6 µM), CYP2C9 (8.0 µM), CYP2B6 (2.1 µM), CYP2D6 (9.5 µM), and CYP3A4 (5.1 µM), respectively, and moderate inhibition towards CYP2C19 (16.4 µM) and CYP2E1 (19.0 µM). These results suggest garcinol may cause herb–drug interactions, mediated by inhibition of CYPs involved in drug metabolism in vivo, by altering pharmacokinetic parameters like AUC and Cmax in a clinically significant manner. Further clinical studies are required to fully assess the safety of garcinol in terms of CYP2B6 and CYP3A4 inhibition.

Garcinol was also found to upregulate the expression and activity of P-glycoprotein (P-gp) in western blotting studies and P-gp inhibition studies in vivo.

8.4 Drug Class Interactions (Based on Garcinia Species Data)

Garcinia may enhance the hepatotoxic effect of green tea; monitoring of therapy is recommended. Selective serotonin reuptake inhibitors (SSRIs): Garcinia may enhance the serotonergic effect of SSRIs, potentially resulting in serotonin syndrome; monitoring is recommended. Theoretically, when used with stomach acid–reducing medications (e.g., proton pump inhibitors), garcinol may provide an additive effect, but should be used cautiously with antioxidant products or cancer medications.

8.5 Bioavailability Limitations

Low aqueous solubility, limited oral absorbance, limited plasma half-life, higher protein binding, and faster metabolic clearance leading to poor bioavailability of garcinol stand as main drawbacks to attaining desirable therapeutic performance; bioavailability studies of garcinol have also been scarcely reported.

The absence of information on its absorption, distribution, metabolism, and elimination (ADME) as well as the absence of detailed toxicity profiles impedes the use of garcinol in clinical studies. This current research gap in toxicological and pharmacokinetic studies warrants further investigations to rationalise and accelerate the development of garcinol as a drug candidate for clinical trials.

References

• Padhye S et al. "Garcinol from Garcinia indica: Chemistry and Health Benefits." ACS Symposium Series, 2013.
• International Journal of Pharmaceutical Research and Applications: "A Review of Garcinia indica — Botanical Features, Phytochemistry and Pharmacology." 2023.
• Journal of University of Shanghai for Science and Technology: "Chemical Constituents and Important Applications of Garcinia Indica."
• Taylor & Francis Knowledge Centers: "Garcinia indica." From Herbs, Shrubs, and Trees of Potential Medicinal Benefits, 2022.
• Semwal RB et al. "Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs." PMC 2009.
• Schobert R & Biersack B. "Chemical and Biological Aspects of Garcinol and Isogarcinol: Recent Developments." Chemistry & Biodiversity, 2019.
• Nayak CA et al. "The chemistry and medicinal uses of the underutilized Indian fruit tree Garcinia indica Choisy (kokum): A review." Food Research International, 2011.
• Ahmad A et al. "Apoptosis-Inducing Effect of Garcinol Is Mediated by NF-kappaB Signaling in Breast Cancer Cells." ResearchGate / Breast Cancer Research, 2010.
• Kopytko P et al. "Garcinol — A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug." International Journal of Molecular Sciences, PMC, 2021.
• PMC: "Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest." 2021.
• Springer Nature: "Garcinol in gastrointestinal cancer prevention: recent advances and future prospects." Journal of Cancer Research and Clinical Oncology, 2024.
• PubMed: Parasramka MA, Gupta SV. "Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells." 2011.
• PMC / Journal of Oncology: Saadat N, Gupta SV. "Potential Role of Garcinol as an Anticancer Agent." 2012.
• PMC / Nutrients: Chantree P et al. "Anti-Inflammatory Effect of Garcinol Extracted from Garcinia dulcis via Modulating NF-κB Signaling Pathway." 2023.
• PMC: "Targeting NF-κB signaling cascades of glioblastoma by a natural benzophenone, garcinol, via in vitro and molecular docking approaches." 2024.
• PMC: "Garcinol Is an HDAC11 Inhibitor." 2021.
• ACS Omega: "Epigenetic Modulation Is a Key Mechanism in Cognitive Deficit: Unveiling Garcinol as a Potent HAT Inhibitor in Improving Alzheimer's Disease." 2026.
• ScienceDirect: "Garcinol enriched fraction of Garcinia morella fruit rind improves gut health and reduces the risk of nonalcoholic fatty liver disease." Food Research International, 2024.
• Drugs.com Natural Products: "Garcinol Uses, Benefits & Dosage." (Cites peer-reviewed literature.)
• PMC: Majeed M et al. "Safety profile of 40% Garcinol from Garcinia indica in experimental rodents." 2018.
• PMC / Membranes: "Cytochrome P450 and P-gp Mediated Herb-Drug Interactions and Molecular Docking Studies of Garcinol." 2021.
• ScienceDirect / Cancer Letters: Liu C et al. "Garcinol: Current status of its anti-oxidative, anti-inflammatory and anti-cancer effects." 2015.
• PMC / Journal of Cancer Research and Clinical Oncology: "Garcinol in gastrointestinal cancer prevention: recent advances and future prospects." 2024.
• Scientific Reports: Gaonkar RH et al. "Garcinol loaded vitamin E TPGS emulsified PLGA nanoparticles." 2017.
• MDPI Polymers: "Garcinol Encapsulated pH-Sensitive Biodegradable Nanoparticles: A Novel Therapeutic Strategy for the Treatment of Inflammatory Bowel Disease." 2021.